Patrick R. O'Neil net worth and biography

Patrick O'Neil Biography and Net Worth

Mr. O’Neil is the Chief Legal Officer and General Counsel of Ionis Pharmaceuticals. He is responsible for managing the legal, patent and GCP QA/QC departments. Mr. O’Neil also serves as Ionis’ corporate secretary. Mr. O’Neil joined Ionis in October 2001.

Prior to joining Ionis, Mr. O’Neil was an associate at Cooley LLP.

Mr. O’Neil received his BS in Business Administration, Finance Concentration from the University of San Francisco and his J.D. at UC Davis School of Law.

What is Patrick R. O'Neil's net worth?: The estimated net worth of Patrick R. O'Neil is at least $1.75 million as of February 20th, 2025. Mr. O'Neil owns 56,245 shares of Ionis Pharmaceuticals stock worth more than $1,752,032 as of March 28th. This net worth evaluation does not reflect any other investments that Mr. O'Neil may own. Learn More about Patrick R. O'Neil's net worth.
How do I contact Patrick R. O'Neil?: The corporate mailing address for Mr. O'Neil and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at wwalke@ionisph.com. Learn More on Patrick R. O'Neil's contact information.
Has Patrick R. O'Neil been buying or selling shares of Ionis Pharmaceuticals?: In the last ninety days, Patrick R. O'Neil has sold $233,983.75 of Ionis Pharmaceuticals stock. Most recently, Patrick R. O'neil sold 1,207 shares of the business's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $32.35, for a transaction totalling $39,046.45. Following the completion of the sale, the executive vice president now directly owns 56,245 shares of the company's stock, valued at $1,819,525.75. Learn More on Patrick R. O'Neil's trading history.
Who are Ionis Pharmaceuticals' active insiders?: Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Michael Hayden (Director), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?: During the last year, Ionis Pharmaceuticals insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $181,100.00. During the last year, insiders at the sold shares 18 times. They sold a total of 144,589 shares worth more than $5,063,297.91. The most recent insider tranaction occured on March, 11th when CEO Brett P Monia sold 140 shares worth more than $4,524.80. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.
Information on this page was last updated on 3/11/2025.

Patrick R. O'Neil Insider Trading History at Ionis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/20/2025	Sell	1,207	$32.35	$39,046.45	56,245
2/4/2025	Sell	6,165	$31.62	$194,937.30	57,452
1/25/2024	Sell	6,450	$51.75	$333,787.50	46,802
12/26/2023	Sell	20,825	$51.46	$1,071,654.50	40,355
5/24/2023	Sell	1,527	$41.70	$63,675.90	40,355
1/30/2023	Sell	4,500	$39.42	$177,390.00	44,179
4/12/2022	Sell	6,792	$40.06	$272,087.52	34,536
1/25/2021	Sell	5,324	$63.50	$338,074.00	26,502
2/10/2020	Sell	3,882	$59.60	$231,367.20	20,720
4/5/2019	Sell	49,528	$83.99	$4,159,856.72	27,327
4/3/2019	Sell	7,654	$84.83	$649,288.82	27,327
3/18/2019	Sell	28,800	$78.79	$2,269,152.00	48,473
2/27/2019	Sell	26,800	$68.01	$1,822,668.00	24,373
2/5/2019	Sell	19,600	$59.25	$1,161,300.00	23,673
1/3/2019	Sell	4,400	$54.80	$241,120.00	14,584
3/12/2018	Sell	1,000	$55.00	$55,000.00	15,452
1/29/2018	Sell	355	$55.00	$19,525.00	14,507
1/25/2018	Sell	645	$55.00	$35,475.00	15,097
12/1/2017	Sell	1,000	$55.50	$55,500.00	11,433
11/1/2017	Sell	1,000	$58.35	$58,350.00	11,433
10/5/2017	Sell	1,000	$55.00	$55,000.00
9/6/2017	Sell	1,000	$55.00	$55,000.00	10,633
6/1/2017	Sell	70	$48.00	$3,360.00	10,369
5/1/2017	Sell	650	$48.75	$31,687.50	10,299
4/24/2017	Sell	500	$45.00	$22,500.00	10,523
4/12/2017	Sell	1,000	$40.07	$40,070.00	10,449
3/1/2017	Sell	1,500	$49.29	$73,935.00	12,949
2/6/2017	Sell	1,500	$46.17	$69,255.00	12,449
12/5/2016	Sell	350	$45.00	$15,750.00	9,876
11/14/2016	Sell	1,000	$45.00	$45,000.00	9,720
4/6/2016	Sell	1,000	$45.00	$45,000.00	10,124
3/23/2016	Sell	1,000	$45.40	$45,400.00	10,124
12/1/2015	Sell	1,000	$61.50	$61,500.00	6,259
11/3/2015	Sell	1,000	$51.95	$51,950.00	6,259
3/19/2015	Sell	30,525	$74.85	$2,284,796.25
1/2/2015	Sell	1,500	$62.12	$93,180.00
12/1/2014	Sell	1,500	$51.21	$76,815.00
11/3/2014	Sell	1,500	$46.17	$69,255.00
10/1/2014	Sell	1,500	$38.04	$57,060.00
8/12/2014	Sell	1,500	$35.00	$52,500.00
7/1/2014	Sell	1,500	$35.33	$52,995.00
9/4/2013	Sell	2,500	$27.09	$67,725.00

See Full Table

Patrick R. O'Neil Buying and Selling Activity at Ionis Pharmaceuticals

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Today's Range

Now: $31.15

$30.80

$31.58

50 Day Range

MA: $32.54

$30.35

$34.75

2 Week Range

Now: $31.15

$30.10

$52.34

Volume

799,700 shs

Average Volume

1,450,942 shs

Market Capitalization

$4.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.28